In the long human struggle against cancer, a Wednesday morning in August 2026 marked a quiet but consequential turning point: Moderna and Merck announced that a personalized mRNA vaccine called intismeran, paired with an established immunotherapy drug, had successfully prevented melanoma from returning in high-risk patients after surgery. For the more than 234,000 Americans diagnosed with melanoma each year — and the 8,500 who die from it — this represents not merely a scientific milestone but a reimagining of what medicine can offer after the surgeon's work is done. The market responded with
Moderna, Merck's melanoma vaccine shows landmark efficacy in trial
Over 8,500 Americans die annually from melanoma; this vaccine could prevent recurrence and death in high-risk patients who have undergone surgery.
The cancer from coming back after you've already had it cut out
Mark
Why does a vaccine for melanoma matter more than, say, a new drug for another cancer?
Mimi
Because melanoma is both common and deadly, and because surgery alone isn't enough for high-risk patients. This vaccine prevents recurrence—it stops the cancer from coming back after you've already had it cut out. That's different from treating cancer that's already spread.
Mark
But it's not a vaccine in the traditional sense, is it? You don't get it before you get sick.
Mimi
Right. It's called a vaccine because it trains the immune system to recognize and attack cancer cells, the way a traditional vaccine teaches your body to fight a virus. But you're correct—you get it after surgery, not before. It's personalized, too. Each vaccine is made specifically for that patient's tumor.
Mark
That sounds expensive and complicated.
Mimi
It probably is, at least initially. But if it prevents recurrence in people who would otherwise face a 50% or higher risk of their cancer coming back, the cost calculation changes. You're potentially saving lives and years of additional treatment.
Mark
The stock price doubled. Is that because investors think this will be approved, or because they're excited about the technology itself?
Mimi
Both, probably. The technology—personalized mRNA cancer treatment—is genuinely novel. But the stock surge is also about the trial results being real and measurable. This wasn't a theoretical advance. It worked in patients.
Mark
What happens next?
Mimi
Regulators review the data. If they approve it, it becomes a new standard of care for high-risk melanoma patients after surgery. That's the inflection point everyone's watching for.
Le Pouls
- Melanoma kills over 8,500 Americans annually, and for high-risk patients who survive surgery, the threat of recurrence has long made recovery feel provisional — this trial directly confronts that dread.
- Intismeran works by personalizing the vaccine to each patient's individual tumor, teaching the immune system to hunt what remains — a level of precision that until recently existed more in aspiration than in clinical reality.
- Combined with Merck's Keytruda, the vaccine prevented both recurrence and spread to distant organs, prompting the study's lead researcher to call it a 'landmark moment' and the first treatment of its kind to reduce the risk of death in melanoma patients.
- Moderna's stock surged 145% in a single day — a market signal that investors believe this advance could define an entirely new standard of post-surgical cancer care, known as adjuvant therapy.
- The unpublished trial data is headed to regulators at an international medical meeting, where the harder, slower work of FDA approval will begin — promising, but not yet promised.
In the long human struggle against cancer, a Wednesday morning in August 2026 marked a quiet but consequential turning point: Moderna and Merck announced that a personalized mRNA vaccine called intismeran, paired with an established immunotherapy drug, had successfully prevented melanoma from returning in high-risk patients after surgery. For the more than 234,000 Americans diagnosed with melanoma each year — and the 8,500 who die from it — this represents not merely a scientific milestone but a reimagining of what medicine can offer after the surgeon's work is done. The market responded with rare conviction, tripling Moderna's share price in a single session, as if the world had collectively recognized that something old and feared had, at last, been answered.
On a Wednesday morning in August, Moderna's stock nearly tripled. The company and its partner Merck had announced that an experimental mRNA vaccine designed to fight melanoma — the deadliest form of skin cancer — had worked in actual patients. Shares surged 145%, closing at $154.48, a market reaction that spoke plainly: something significant had shifted in cancer treatment.
The vaccine, called intismeran, targets melanoma patients who have already undergone surgery to remove their tumors but remain at serious risk of recurrence. More than 234,000 Americans are diagnosed with melanoma each year, and over 8,500 die from it annually. The disease spreads with a ruthlessness that has made it one of oncology's most feared adversaries. What made this trial different was its approach: the vaccine is personalized, engineered for each patient's individual cancer, and designed to teach the immune system to recognize and destroy melanoma cells. Paired with Merck's established immunotherapy drug Keytruda, it prevented both recurrence and spread to distant organs.
Professor Georgina Long, who led the study at the University of Sydney, called the results a 'landmark moment' — the first treatment of its kind to demonstrably reduce the risk of recurrence or death in melanoma patients. If approved, it could establish an entirely new standard of post-surgical care. Merck's stock also rose sharply, and both companies' leaders framed the moment in expansive terms: early intervention, personalized medicine, and the transformation of what once seemed like aspiration into clinical reality.
The unpublished data will be presented to regulators at an upcoming international medical meeting — the next critical step on a path toward FDA approval that is promising but not guaranteed. For melanoma patients and their physicians, the question now belongs to the regulators.
On a Wednesday morning in August, Moderna's stock price nearly tripled. The reason: the company and its partner Merck had just announced that an experimental vaccine—one designed to fight melanoma, the deadliest form of skin cancer—had worked. Not in a laboratory dish, but in actual patients. Shares jumped $91.52 to close at $154.48, a 145% surge that sent a clear signal through the market: something significant had happened in cancer treatment.
The vaccine is called intismeran, and it represents a fundamental shift in how doctors might approach melanoma after surgery. The study focused on high-risk patients who had already undergone surgery to remove their tumors. These are people at serious risk of recurrence—the cancer coming back, spreading to other parts of the body, potentially becoming fatal. More than 8,500 Americans die from melanoma each year. Over 234,000 new cases are diagnosed annually. The disease begins in melanocytes, the cells responsible for skin pigmentation, and it spreads with a ruthlessness that has made it one of oncology's most feared adversaries.
What made this trial different was the approach. Moderna's vaccine is personalized—designed specifically for each patient's individual cancer. It works by teaching the immune system to recognize and attack melanoma cells. In the study, intismeran was paired with Keytruda, Merck's established immunotherapy drug. Together, they kept cancer from returning and prevented it from spreading to distant organs. This is not a cure in the traditional sense. It is prevention of recurrence, which for cancer patients amounts to something close to it.
Professor Georgina Long, who led the study at the University of Sydney, called the results a "landmark moment." She emphasized that this is the first treatment of its kind to demonstrate it could reduce the risk of recurrence or death in melanoma patients. The implications are substantial. If approved by regulators, this approach could establish an entirely new standard of care—what doctors call adjuvant therapy, meaning treatment given after surgery to prevent the cancer from returning. The goal is straightforward: keep more patients cancer-free for longer.
Merck's stock also climbed, rising $14.35 or about 10.6% on the news. Dr. Dean Y. Li, president of Merck Research Laboratories, framed the advance in clinical terms: intervening early, when cancers are most treatable, increases the possibility of cure. Moderna's CEO Stéphane Bancel went further, describing the moment as pivotal for cancer research itself. For years, he said, the idea of creating an mRNA treatment tailored to an individual patient's tumor seemed like aspiration rather than achievable medicine. Now it was real.
The unpublished data will be presented to regulators at an upcoming international medical meeting. That presentation will be the next critical step—the moment when the scientific community and regulatory agencies examine the evidence in detail. Approval is not guaranteed, and the path from promising trial results to available treatment is rarely straightforward. But the market's reaction on Wednesday morning suggested that investors, at least, believe something has shifted. Moderna's stock, which had fallen far from its pandemic-era peaks in 2021 and 2022 when COVID vaccines drove extraordinary demand, suddenly looked like it might have found a new chapter. For melanoma patients and their doctors, the question now is whether the regulators will agree.
Citations marquantes
Today's results represent a landmark moment for adjuvant melanoma treatment, and this is the first treatment of its kind to show it can reduce the risk of recurrence or death in patients.— Professor Georgina Long, principal investigator, University of Sydney
For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.— Stéphane Bancel, CEO of Moderna
Envie de l'histoire complète ?
Lire l'original sur CBS News ↗
Health & Medicine